NHSL3

NHSL3 (KIAA1522) is a multi-isoform member of the Nance-Horan Syndrome family that regulates actin-based cell migration through isoform-specific protein interactions at the leading edge and at cell-cell junctions (PMID:39747206). Loss of NHSL3 increases persistence of single-cell migration while impairing collective migration, reflecting two genetically separable functions (PMID:39747206): a long isoform binds MENA/VASP proteins at cell-cell junctions to enable collective migration, whereas a short isoform binds 14-3-3θ in lamellipodia to set single-cell migration persistence, with binding-site mutations abolishing each rescue (PMID:39747206). At the lamellipodial edge NHSL3 co-localizes with Ena/VASP and the Scar/WAVE complex and inhibits Scar/WAVE-Arp2/3 activity [PMID:bio_10.1101_2025.04.03.647056], engaging the complex through both its Abi and CYFIP1/2 subunits via three short linear motifs [PMID:bio_10.1101_2025.04.03.647056]. Beyond motility, KIAA1522 promotes tumor cell proliferation, survival, and chemoresistance by activating ERK (PMID:28794639), TNFα-TNFR2-NFκB (PMID:32854746), Wnt/β-catenin (PMID:32606779), and Notch (PMID:34826587) signaling. Its expression is controlled transcriptionally by KLF9, which binds the KIAA1522 promoter and represses it (PMID:38520660), and epigenetically through a PLACT1-EHMT2-KLF2 axis that de-represses KIAA1522 (PMID:41164921); alternative first-exon usage generates state-specific isoforms in pluripotent cells that differ in N-terminal domain, localization, and effect on LTR retrotransposon activity (PMID:40553414).

1. 2017 Medium

   Established the first molecular handle on KIAA1522 function by linking it to a defined growth-signaling readout, addressing why its expression correlates with tumor aggressiveness.

   Evidence siRNA knockdown with phospho-ERK Western blot, proliferation/anoikis assays, and xenograft/metastasis models in esophageal squamous cell carcinoma

   PMID:28794639

   Open questions at the time

   • Does not show direct molecular interaction between KIAA1522 and ERK pathway components
   • Mechanism of ERK activation unresolved
2. 2020 Medium

   Extended KIAA1522's pro-tumor role to additional survival pathways, showing it potentiates NFκB and Wnt/β-catenin signaling and drives chemoresistance.

   Evidence In vivo KrasG12D/Cas9 model with AAV-sgRNA depletion plus NFκB inhibitor rescue (lung adenocarcinoma); TOP/FOP-flash luciferase reporters (hepatocellular carcinoma)

   PMID:32606779 PMID:32854746

   Open questions at the time

   • Direct binding partners connecting KIAA1522 to NFκB/Wnt not identified
   • Whether pathway activation is direct or secondary unknown
3. 2021 Medium

   Added Notch as a fourth oncogenic pathway downstream of KIAA1522, reinforcing its role in proliferation, invasion, and metastasis.

   Evidence Transcriptome sequencing, GSEA, Western blot, IHC and tail-vein metastasis model in colorectal cancer

   PMID:34826587

   Open questions at the time

   • Mechanism linking KIAA1522 to Notch activation not defined
   • No physical interaction demonstrated
4. 2024 Medium

   Answered how KIAA1522 levels are set transcriptionally, identifying KLF9 as a direct promoter-binding repressor.

   Evidence ChIP and dual-luciferase reporter with overexpression/knockdown rescue in pancreatic cancer

   PMID:38520660

   Open questions at the time

   • Upstream regulators of KLF9 in this context not defined
   • Single tumor type
5. 2025 High

   Resolved the core cell-biological function of NHSL3, demonstrating isoform-specific interactions that partition single-cell versus collective migration control.

   Evidence Knockout cell lines, wound healing and single-cell tracking, isoform-specific proteomics, AlphaFold2 binding prediction, and binding-site mutagenesis rescue (Nature Communications)

   PMID:39747206

   Open questions at the time

   • Structural basis of the MENA/VASP and 14-3-3θ interactions not determined
   • How isoform choice is regulated across tissues unknown
6. 2025 Medium

   Defined a molecular mechanism for NHSL3's effect on the actin machinery by showing it binds and inhibits the Scar/WAVE-Arp2/3 system.

   Evidence Co-localization imaging, pulldown/Co-IP, short linear motif mapping, and cellular Arp2/3 activity assay (bioRxiv preprint)

   PMID:bio_10.1101_2025.04.03.647056

   Open questions at the time

   • Preprint, single lab
   • In vitro reconstitution of Arp2/3 inhibition not shown
   • Functional consequence of dual Abi/CYFIP binding unresolved
7. 2025 Medium

   Uncovered an epigenetic axis and a nuclear, isoform-dependent function, broadening KIAA1522 beyond cytoplasmic migration into transcriptional/chromatin contexts.

   Evidence ChIP/RNA pulldown/xenograft for the PLACT1-EHMT2-KLF2 axis; RNA-seq, CUT&Tag and localization for state-specific ESC isoforms regulating LTR retrotransposons

   PMID:40553414 PMID:41164921

   Open questions at the time

   • Direct chromatin-binding activity of nuclear NHSL3 isoforms not characterized
   • Mechanism by which isoforms affect LTR activity unknown
   • Single lab per finding

• How the distinct isoform-specific cytoplasmic (migration), oncogenic signaling, and nuclear (retrotransposon) functions are coordinated within and across cell types remains unresolved.
• No unifying biochemical activity defined for the protein
• Relationship between migration role and oncogenic signaling not established
• No structural model of the protein